Drug Profile
Research programme: palmitoyl-acyltransferase inhibitors - Apogee Biotechnology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Apogee Biotechnology Corporation
- Class
- Mechanism of Action Acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)